AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 APR 3 - (NewsRx.com & NewsRx.net) -- Zidovudine prophylaxis against vertical HIV transmission has no long-term adverse effects.
Treatment with the antiretroviral agent "is recommended to reduce perinatal HIV-1 transmission, but there are limited data on long-term effects on women's health," researchers in the United States explained. The "Pediatrics AIDS Clinical Trials Group (PACTG) 288 was a prospective observational study among US women randomized to zidovudine or placebo in PACTG 076 that was designed to evaluate and compare postpartum clinical, immune, and viral parameters between randomized treatment arms."
"Forty-eight percent (226/474) of eligible women enrolled in the study (mean follow-up of 4.1 years)," according to A. D. Bardeguez and coauthors at the University of Medicine and Dentistry of New Jersey. "Progression and time to AIDS or death were similar in both groups, observed in 21 (19%) zidovudine group women and 29 (25%) placebo group women (RR = 0.73, 90% CI: 0.46-1.17)."
Moreover, "no significant differences in CD4+ lymphocyte count or HIV RNA levels were detected" between zidovudine-treated women and controls, study data showed. "Genotypic zidovudine resistance was detected in 10% of 156 women (9% of zidovudine group women and 11% of placebo group women)."
"Based ...
Source: HighBeam Research, Zidovudine prophylaxis has no long-term adverse effects.